Transcode Therapeutics, INC 8-K filings

TransCode Therapeutics, Inc. announced the approval of several key proposals at its 2026 Annual Meeting of Stockholders, including stock issuances and director elections.

TransCode Therapeutics, Inc. has amended its Certificate of Designation for Series C Non-Voting Convertible Preferred Stock, increasing the beneficial ownership limitation.

TransCode Therapeutics shared an update on its three-platform oncology pipeline, highlighting progress in its lead candidate TTX-MC138 and future development plans.

TransCode Therapeutics announced positive safety and disease stabilization data from its Phase 1a clinical trial of TTX-MC138 in metastatic cancer patients, advancing to Phase 2 development.

TransCode Therapeutics announced its 2026 Annual Meeting of Stockholders will be held on July 2, 2026, with a record date of May 28, 2026.

TransCode Therapeutics has received a deficiency letter from Nasdaq for failing to meet the minimum stockholders equity requirement and is developing a plan to regain compliance.

TransCode Therapeutics has been notified by Nasdaq that it fails to meet the minimum stockholders' equity requirement for continued listing.

TransCode Therapeutics has entered into a $20 million flexible financing arrangement with Yorkville Advisors to fund its lead oncology clinical program through late 2027.

TransCode Therapeutics has secured an exclusive, worldwide license for a preclinical oncolytic immunotherapy platform from Unleash Immuno Oncolytics, Inc., expanding its oncology pipeline.

TransCode Therapeutics announced the publication of preclinical data for a novel tumor-selective RIG-I immunotherapeutic candidate, supporting its further development.

TransCode Therapeutics and Quantum Leap Healthcare Collaborative submitted an IND amendment for a planned Phase 2a clinical trial of TTX-MC138 for colorectal cancer.

TransCode Therapeutics announced preclinical data supporting its lead candidate TTX-MC138 for glioblastoma treatment, showing extended survival in models.

TransCode Therapeutics, Inc. finalized its acquisition of immuno-oncology firm ABCJ, LLC, parent of Polynoma, and disclosed pro forma financials and significant integration risks.

TransCode Therapeutics strengthens its Board of Directors with the appointment of Jack Stover, an experienced financial expert and life sciences executive.

TransCode Therapeutics partners with Quantum Leap Healthcare Collaborative to advance its lead candidate, TTX-MC138, into a Phase 2a clinical trial for colorectal cancer.

TransCode Therapeutics, Inc. filed an amended certificate of designation for its Series A and B Preferred Stock, clarifying conversion limits and removing delisting conversion rights to comply with Nasdaq rules.

TransCode Therapeutics, Inc. filed an amendment to its Current Report on Form 8-K, detailing the effective date and terms of a Contingent Value Rights Agreement related to the monetization of its TTX-MC138 program assets.

TransCode Therapeutics announced the successful completion of its Phase 1a clinical trial for TTX-MC138, achieving its primary safety endpoint and defining a recommended Phase 2 dose.

TransCode Therapeutics, Inc. filed an amendment to correct the Series B Preferred Stock price in its recent acquisition of ABCJ, LLC and concurrent $25 million private placement.

TransCode Therapeutics expands its oncology pipeline with the acquisition of Polynoma and secures a $25 million strategic investment from CK Life Sciences, appointing a new CEO and Board member.

TransCode Therapeutics, Inc. has amended its exclusive patent license agreement with Massachusetts General Hospital, updating timelines and significantly increasing potential milestone payments for two patent families.

TransCode Therapeutics, Inc. stockholders approved the election of all director nominees and all proposals, including a stock plan amendment and auditor ratification, at the 2025 Annual Meeting.

TransCode Therapeutics, Inc. has announced a change in the date for its 2025 annual meeting of stockholders to August 29, 2025, and has set new deadlines for stockholder proposals and director nominations.

TransCode Therapeutics received a delisting notice from Nasdaq for failing to maintain a minimum closing bid price of $1.00 per share.

TransCode Therapeutics will implement a 1-for-28 reverse stock split effective May 15, 2025, to meet Nasdaq's minimum bid price requirement.

TransCode Therapeutics' stockholders approved a 1-for-28 reverse stock split aimed at increasing the company's stock price to meet Nasdaq's minimum bid requirement.

TransCode Therapeutics adjourns its special meeting of stockholders due to insufficient quorum and reschedules it for May 2, 2025, to allow for additional proxy solicitation.

TransCode Therapeutics has agreed to sell shares and warrants in a registered direct offering, expecting gross proceeds of approximately $10 million.

TransCode Therapeutics announces stockholder approval of proposals concerning warrant issuance and potential meeting adjournment at a special meeting held on February 25, 2025.

TransCode Therapeutics adjourns its special meeting of stockholders due to insufficient quorum and reschedules it for February 25, 2025, to allow for additional proxy solicitation.